BioNTech SE stated on Monday that it had started its work on vaccine adapted to Omicron, the new worrying coronavirus strain found in South Africa, though it wasn’t clear enough if it would have to again work its already developed Covid-19 shot.
The development of an already developed vaccine is part of the standard of the company procedure for new strains, BioNTech that makes vaccines along with Pfizer, stated in a statement.
“The first steps of developing a potential new vaccine overlap with the research necessary in order to evaluate whether a new shot will be needed,” it further added.
The Omicron strain has a high global risk of increasing cases, the WHO warned as more nations reported cases on Monday, reminding border closures.
BioNTech had stated it expects much more lab data over the upcoming next 2 weeks to help determine if there is any need for a vaccine-related to Omicron. Rival Moderna has stated that it was working on another design of its COVID-19 vaccine for future booster shots.